SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 190.54 |
| Enterprise Value ($M) | 133.58 |
| Book Value ($M) | 430.87 |
| Book Value / Share | 6.11 |
| Price / Book | 0.44 |
| NCAV ($M) | 188.99 |
| NCAV / Share | 2.68 |
| Price / NCAV | 1.01 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.21 |
| Return on Assets (ROA) | -0.27 |
| Return on Equity (ROE) | -0.37 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 12.91 |
| Current Ratio | 12.91 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 290.15 |
| Assets | 532.03 |
| Liabilities | 101.16 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Flynn James E | 3.05 | -36.62 | |
| 13G/A | Commodore Capital Lp | 6.60 | 70.77 | |
| 13G/A | Adage Capital Management, L.P. | 5.10 | ||
| 13G | BlackRock, Inc. | 6.00 | 0.00 | |
| 13G/A | Boxer Capital Management, LLC | 4.90 | ||
| 13D/A | Samsara BioCapital, L.P. | 5.40 | 31.38 | |
| 13D/A | Ra Capital Management, L.p. | 18.90 | 76.81 | |
| 13D/A | Glaxosmithkline Plc | 4.50 | 0.00 | |
| 13D/A | New Enterprise Associates 15, L.P. | 5.10 | 0.00 | |
| 13D/A | LSP 6 Holding C.V. | 5.80 | 30.72 | |
| 13G/A | Adage Capital Partners Gp, L.l.c. | 7.03 | -6.76 | |
| 13G | Boxer Capital, LLC | 9.00 | ||
| 13G/A | T. Rowe Price Investment Management, Inc. | 0.80 | -91.68 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 312,923 | 1,197,848 | 26.12 | |
| 181,026 | 1,033,974 | 17.51 | |
| 168,892 | 627,227 | 26.93 | |
| 179,218 | 758,726 | 23.62 | |
| 252,060 | 1,312,987 | 19.20 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| MYGN – Myriad Genetics, Inc. | NBIX – Neurocrine Biosciences, Inc. |
| NEOG – Neogen Corporation | NMRA – Neumora Therapeutics, Inc. |
| NUVL – Nuvalent, Inc. |
Financial data and stock pages provided by
Fintel.io